Market Overview

Information Update - Certain Metformin diabetes drugs recalled due to the presence of NDMA

Share:

OTTAWA, Feb. 26, 2020 /CNW/ -

Summary

Products: Certain brands of diabetes drugs containing metformin.

Issue: Products contain a nitrosamine impurity, N-nitrosodimethylamine (NDMA), above or close to the acceptable limit.

What to do: You should not stop taking your metformin drug without first discussing options with your health care provider. Talk to your health care provider to discuss treatment options if you are taking or have taken a recalled product and are concerned about your health.

UPDATE: February 26, 2020

Ranbaxy Pharmaceuticals Canada Inc. is recalling six lots of its prescription RAN-Metformin drug from the Canadian market. Company testing identified two lots (#AJY8006A and #AJY8007A) with levels of NDMA above what is considered acceptable if the drug were to be taken over a lifetime. The company is recalling an additional four lots (#AJY8005A, #AJY8005B, #AJY8008A and #AJZ8005A) as a precautionary measure because they contain NDMA close to the acceptable limit. Please refer to the Affected products table below for detailed information on the recalled lots.

Should any additional recalls be necessary, Health Canada will update the table below and inform Canadians.

Original Information Update: February 5, 2020 - Apotex Inc. recalls certain lots of the diabetes medication APO-Metformin ER (extended release) 500 mg tablets

Issue
Apotex Inc. is recalling eight lots of its 500 mg extended release metformin tablets ("APO-Metformin ER") because they contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) above the acceptable limit. Apotex Inc. has tested all lots of its 500 mg extended release tablets; only the affected lots are being recalled (see table below). There are also alternative metformin products on the Canadian market manufactured by other companies.

Metformin is a prescription drug used to control high blood sugar in patients with type 2 diabetes.

Individuals taking metformin, including a recalled product, should not stop taking it unless they have spoken to their health care provider as the risks from not having adequate diabetes treatment outweigh any possible effects of exposure to the levels of NDMA found in the recalled products.

NDMA is classified as a probable human carcinogen. We are all exposed to low levels of nitrosamines through a variety of foods (such as smoked and cured meats, dairy products and vegetables), drinking water and air pollution. NDMA is not expected to cause harm when ingested at low levels. A person taking a drug that contains NDMA at or below the acceptable level every day for 70 years is not expected to have an increased risk of cancer.

In December 2019, Health Canada communicated that it is assessing the issue of NDMA in metformin products, after some metformin products available outside Canada were detected to contain NDMA above the acceptable limit. The Department asked companies to test their metformin products and is conducting testing in its own laboratories. Health Canada is also working closely with international regulatory partners, including the U.S. Food and Drug Administration and the European Medicines Agency, to inform its assessment. Health Canada continues to assess this issue, and will update the table below and inform Canadians should any additional recalls be necessary.

Health Canada has been working to address the issue of NDMA and other nitrosamine impurities found in certain medications since the summer of 2018. Health Canada continues to work closely with international regulatory partners to address the issue. The Department will take action if a new risk to Canadians is identified, and will continue to inform the public of new safety information.

Who is affected
Patients who are taking an affected metformin drug.

What consumers should do

  • You should not stop taking your metformin drug without first discussing options with your health care provider. The risks from not having adequate diabetes treatment outweigh any possible effects of exposure to the levels of NDMA found in the recalled products. Stopping metformin medication could lead to uncontrolled diabetes, which can cause serious health problems such as:
    • High blood sugars. Symptoms of high blood sugars include increased urination, thirst, excessive hunger, fatigue, blurred vision, drowsiness, irritability, unintended weight loss and dizziness. Very high blood sugars can lead to effects such as vomiting, diarrhea, dehydration, confusion, agitation and coma.
    • Longer-term health impacts. These include heart disease, nerve problems, kidney damage, blindness and amputations.
  • Talk to your health care provider to discuss treatment options if you are taking a recalled product or if you have taken a recalled product and are concerned about your health.
    • Ask your pharmacist if you are unsure whether you are taking a recalled product.
  • Report any health product adverse events or complaints to Health Canada.
  • Contact the company directly if you have questions about a recall:
    • Apotex Inc. via Stericycle ULC by calling toll-free at 1-855-853-9461.
    • Ranbaxy Pharmaceuticals Canada Inc. by calling toll-free at 1-866-840-1340, or by email at canadacustomerservice@sunpharma.com

Affected products
The following is a list of metformin drugs being recalled in Canada at this time:

 

Company

Product Name/Active Pharmaceutical Ingredient (API)

DIN

Strength

Lot

Expiry

Apotex Inc.

APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets)

02305062

500 mg

NV3242

04/2020

NV3244

04/2020

NV3245

04/2020

NV3243

04/2020

NV3247

04/2020

NV3248

04/2020

PX5334

01/2021

PX5335

01/2021

Ranbaxy Pharmaceuticals Canada Inc.

RAN-Metformin

02269031

500 mg

AJY8006A

05/2020

500 mg

AJY8007A

05/2020

500 mg

AJY8005A

05/2020

500 mg

AJY8005B

05/2020

500 mg

AJY8008A

05/2020

850 mg

AJZ8005A

05/2020

 

Related links

Également disponible en français

SOURCE Health Canada

View original content: http://www.newswire.ca/en/releases/archive/February2020/26/c3340.html

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com